Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia

Basit Öğe Kaydı
dc.authoridZhumatayev, Suleimen/0000-0002-4409-8180
dc.contributor.authorZhumatayev, Suleimen
dc.contributor.authorYalcin, Koray
dc.contributor.authorCelen, Safiye Suna
dc.contributor.authorKaraman, Irem
dc.contributor.authorDaloglu, Hayriye
dc.contributor.authorOzturkmen, Seda
dc.contributor.authorUygun, Vedat
dc.date.accessioned2024-05-19T14:38:57Z
dc.date.available2024-05-19T14:38:57Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjectives: Graft-versus-host disease (GvHD) is one of the leading causes of morbidity and mortality in patients undergoing allogeneic HSCT, and effective prevention of GvHD is critical for the success of the HSCT procedure. Calcineurin inhibitors (CNI) have been used for decades as the backbone of GvHD prophylaxis. In this study, the efficacy and safety of Cyclosporine A (CsA) and tacrolimus (TCR) were compared in pediatric HSCT for thalassemia. Materials and Methods: This is a retrospective analysis of 129 pediatric patients who underwent HSCT with the diagnosis of thalassemia at Medicalpark Goztepe and Antalya Hospitals between January 2017 and December 2020. Results: Despite the GvHD prophylaxis, grade II-IV acute GvHD developed in 29 patients. Of these patients, 12 had only gut, 10 had only skin, 6 had combined gut and skin, and one had only liver GvHD. Fifteen of these 29 patients were in the CsA group, and 14 of them were in the TCR group. There was no significant difference between the groups in terms of acute GvHD occurrence, GvHD stage, or involvement sites. In terms of CNI-related toxicity, neurotoxicity in 15 (CsA n = 9, TCR n = 6) and nephrotoxicity in 18 (CsA n = 4, TCR n = 14) patients were observed. While there was no difference between the two groups in terms of neurotoxicity, more nephrotoxicity developed in patients using TCR (p = .013). There was no significant difference between the groups in terms of engraftment syndrome, veno-occlusive disease, CMV reactivation, PRES, or graft rejection. Conclusion: Regarding GvHD, there was no difference in efficacy between TCR and CsA usage. Patients taking TCR experienced noticeably higher nephrotoxicity in terms of adverse effects. This difference should be considered according to the patient's clinical situation while choosing a CNI.en_US
dc.identifier.doi10.1111/petr.14688
dc.identifier.issn1397-3142
dc.identifier.issn1399-3046
dc.identifier.issue1en_US
dc.identifier.pmid38317344en_US
dc.identifier.scopus2-s2.0-85183616360en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1111/petr.14688
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4659
dc.identifier.volume28en_US
dc.identifier.wosWOS:001151998700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAllogeneic Stem Cell Transplantationen_US
dc.subjectCalcineurin Inhibitorsen_US
dc.subjectCyclosporineen_US
dc.subjectGraft-Vs-Host Diseaseen_US
dc.subjectPediatric Transplantationen_US
dc.subjectTacrolimusen_US
dc.titleComparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu